A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)

By afschroeder • June 8, 2025

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC; University of California Hematologic Malignancies Consortium. A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leuk Res. 2025 Jun 2;155:107717. doi: 10.1016/j.leukres.2025.107717. Epub ahead of print. PMID: 40479857.

Tags: Azacitidine, Hematology/Oncology, Ibrutinib, Myelodysplastic syndromes, Publications

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels

Sonni I, Gulpe A, Nickols NG, Schaffer D, Montagut L, Berenji GR, Rettig MB. Early detection and localization of recurrent prostate cancer using [Formula: see[...]

Lung Cancer Screening in California and Los Angeles County: A Landscape Analysis

Tupper HI, Gao YA, Cummings AL. Lung Cancer Screening in California and Los Angeles County: A Landscape Analysis. Cureus. 2026 Jun 27;18(6):e111619. doi: 10.7759/cureus.111619. PMID:[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]